Please Wait.....

Report

Asia-Pacific Traumatic Brain Injury Treatment Market?

Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research

Asia-Pacific traumatic brain injury treatment market is expected to reach USD 1.448.48 million by 2032 from USD 792.22 million in 2024, growing at a substantial CAGR of 7.9% in the forecast period of 2025 to 2032.
Market Segmentation:
Asia-Pacific Traumatic Brain Injury Treatment Market, By Treatment (Surgery, Immediate Emergency Care, and Medications), Route of Administration (Parenteral, Oral, and Others), Patient Age (Children, Teenager, and Elder), Gender (Male and Female), Cause of Injury (Falls, Motor Vehicle Traffic, Sports, and Others), End User (Hospitals, Neurology Clinics, Independent Pharmacies, and Others), Country (China, Japan, India, Australia, South Korea, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends & Forecast To 2032
Overview of the Asia-Pacific Traumatic Brain Injury Treatment Market are:

Driver

- Increasing Incidence of Traumatic Brain Injury (TBI)

Restraint

- Shortage Of Trained Neurologists and Neurosurgeons
Opportunity

- Rising Personalized & Targeted Therapies in Traumatic Brain Injury (TBI)

Market Players:

The key market players for Asia-Pacific traumatic brain injury treatment market are listed below:

- Pfizer Inc.
- Teva Pharmaceuticals USA, Inc.
- Fresenius SE & Co. KGaA (Fresenius Kabi AG)
- Viatris Inc.
- Amneal Pharmaceuticals LLC
- Dr. Reddy's Laboratories Ltd.
- Sun Pharmaceutical Industries, Inc.
- Lupin
- Hikma
- Aurobindo Pharma USA
- Alembic Pharmaceuticals Limited

TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF THE ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET 27
1.4 LIMITATIONS 28
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 31
2.1 MARKETS COVERED 31
2.2 GEOGRAPHICAL SCOPE 32
2.3 YEARS CONSIDERED FOR THE STUDY 33
2.4 CURRENCY AND PRICING 33
2.5 DBMR TRIPOD DATA VALIDATION MODEL 34
2.6 MULTIVARIATE MODELLING 37
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 38
2.8 DBMR MARKET POSITION GRID 39
2.9 MARKET END-USER COVERAGE GRID 40
2.10 VENDOR SHARE ANALYSIS 41
2.11 SECONDARY SOURCES 42
2.12 ASSUMPTIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 46
4.1 PORTER'S FIVE FORCES 49
4.2 PESTEL ANALYSIS 50
4.3 TECHNOLOGY ROADMAP 51
4.4 VALUE CHAIN ANALYSIS 51
4.5 OPPUTUNITY MAP ANALYSIS 52
4.6 REIMBURSEMENT FRAMEWORK 52
4.7 COST ANALYSIS BREAKDOWN 53
4.8 PENETRATION AND GROWTH PROSPECT MAPPING: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET 54
4.9 KEY PRICING STRATEGIES: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET 55
4.10 MICRO AND MACRO-ECONOMIC FACTORS: ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET 56
5 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, REGULATORY FRAMEWORK 59
6 MARKET OVERVIEW 63
6.1 DRIVERS 65
6.1.1 INCREASING INCIDENCE OF TRAUMATIC BRAIN INJURY (TBI) 65
6.1.2 GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES IN TBI TREATMENT 66
6.1.3 TECHNOLOGICAL ADVANCEMENT FOR DIAGNOSIS OF TRAUMATIC BRAIN INJURIES (TBI) 67
6.1.4 ADVANCEMENTS IN NEUROPROTECTION AND PHARMACOTHERAPY FOR TBI TREATMENT 68
6.2 RESTRAINTS 70
6.2.1 SHORTAGE OF TRAINED NEUROLOGISTS AND NEUROSURGEONS 70
6.2.2 HIGH COST OF TRAUMATIC BRAIN INJURY (TBI) TREATMENT 70
6.3 OPPORTUNITIES 72
6.3.1 RISING PERSONALIZED & TARGETED THERAPIES IN TRAUMATIC BRAIN INJURY (TBI) 72
6.3.2 GROWING BRAIN STIMULATION TECHNIQUES IN TRAUMATIC BRAIN INJURY (TBI) TREATMENT 73
6.3.3 RISING ARTIFICIAL INTELLIGENCE (AI) APPLICATIONS IN DIAGNOSING TRAUMATIC BRAIN INJURY (TBI) 74
6.4 CHALLENGES 75
6.4.1 DIFFICULTIES IN OVERCOMING THE BLOOD-BRAIN BARRIER FOR TBI TREATMENT 75
6.4.2 ABSENCE OF STANDARDIZED TREATMENT PROTOCOLS IN TRAUMATIC BRAIN INJURY MANAGEMENT 76
7 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY TREATMENT 77
7.1 OVERVIEW 78
7.2 SURGERY 81
7.2.1 BRAIN BLEEDING TREATMENT 82
7.2.2 REHABILITATION 82
7.2.3 CLOTTED BLOOD REMOVAL 82
7.2.4 WINDOW OPENING IN SKULL 82
7.2.5 REPAIRING SKULL FRACTURES 82
7.3 IMMEDIATE EMERGENCY CARE 82
7.4 MEDICATIONS 83
7.4.1 DIURETICS 84
7.4.2 ANTI-SEIZURE DRUGS (ANTI-CONVULSANT) 84
7.4.3 ANALGESIC 84
7.4.4 COMA-INDUCING DRUGS 84
7.4.5 ANTI-DEPRESSANTS 84
7.4.6 ANTI-ANXIETY AGENT 84
7.4.7 ANTI-PSYCHOTICS 84
7.4.8 ANTI-COAGULANTS 84
7.4.9 OTHERS 85
7.4.9.1 Parenteral 85
7.4.9.2 Oral 85
7.4.9.3 Others 85
8 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY PATIENT AGE 86
8.1 OVERVIEW 87
8.2 CHILDREN 90
8.3 TEENAGER 90
8.4 ELDER 91
9 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY GENDER 92
9.1 OVERVIEW 93
9.2 MALE 96
9.3 FEMALE 96
10 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, CAUSE OF INJURY 97
10.1 OVERVIEW 98
10.2 FALLS 101
10.3 MOTOR VEHICLE TRAFFIC 101
10.4 SPORTS 102
10.5 OTHERS 102
11 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY END USER 103
11.1 OVERVIEW 104
11.2 HOSPITALS 107
11.3 NEUROLOGY CLINICS 107
11.4 INDEPENDENT PHARMACIES 108
11.5 OTHERS 108
12 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET, BY REGION 109
12.1 ASIA-PACIFIC 111
12.1.1 CHINA 116
12.1.2 JAPAN 120
12.1.3 INDIA 124
12.1.4 SOUTH KOREA 128
12.1.5 AUSTRALIA 132
12.1.6 SINGAPORE 136
12.1.7 THAILAND 140
12.1.8 MALAYSIA 144
12.1.9 INDONESIA 148
12.1.10 TAIWAN 152
12.1.11 NEW ZEALAND 156
12.1.12 PHILIPPINES 160
12.1.13 VIETNAM 164
12.1.14 REST OF ASIA-PACIFIC 168
13 ASIA-PACIFIC TRAUMATIC BRAIN INJURY TREATMENT MARKET: COMPANY LANDSCAPE 169
13.1 COMPANY SHARE ANALYSIS: GLOBAL 169
14 SWOT ANALYSIS 170
15 COMPANY PROFILES 171
15.1 PFIZER INC. 171
15.1.1 COMPANY SNAPSHOT 171
15.1.2 REVENUE ANALYSIS 172
15.1.3 COMPANY SHARE ANALYSIS 172
15.1.4 PRODUCT PORTFOLIO 173
15.1.5 RECENT DEVELOPMENT 174
15.2 TEVA PHARMACEUTICALS USA, INC. 175
15.2.1 COMPANY SNAPSHOT 175
15.2.2 REVENUE ANALYSIS 175
15.2.3 COMPANY SHARE ANALYSIS 176
15.2.4 PRODUCT PORTFOLIO 176
15.2.5 RECENT DEVELOPMENT/NEWS 177
15.3 FRESENIUS SE & CO. KGAA (FRESENIUS KABI AG) 178
15.3.1 COMPANY SNAPSHOT 178
15.3.2 REVENUE ANALYSIS 178
15.3.3 COMPANY SHARE ANALYSIS 179
15.3.4 PRODUCT PORTFOLIO 179
15.3.5 RECENT DEVELOPMENT 180
15.4 VIATRIS INC. 182
15.4.1 COMPANY SNAPSHOT 182
15.4.2 REVENUE ANALYSIS 182
15.4.3 COMPANY SHARE ANALYSIS 183
15.4.4 PRODUCT PORTFOLIO 183
15.4.5 RECENT DEVELOPMENT 184
15.5 AMNEAL PHARMACEUTICALS LLC 185
15.5.1 COMPANY SNAPSHOT 185
15.5.2 REVENUE ANALYSIS 185
15.5.3 COMPANY SHARE ANALYSIS 186
15.5.4 PRODUCT PORTFOLIO 186
15.5.5 RECENT DEVELOPMENT 187
15.6 ADVACARE PHARMA 188
15.6.1 COMPANY SNAPSHOT 188
15.6.2 PRODUCT PORTFOLIO 188
15.6.3 RECENT DEVELOPMENT 190
15.7 AUROBINDO PHARMA LIMITED 191
15.7.1 COMPANY SNAPSHOT 191
15.7.2 REVENUE ANALYSIS 192
15.7.3 PRODUCT PORTFOLIO 192
15.7.4 RECENT DEVELOPMENT 193
15.8 ALEMBIC PHARMACEUTICALS LIMITED 194
15.8.1 COMPANY SNAPSHOT 194
15.8.2 REVENUE ANALYSIS 195
15.8.3 PRODUCT PORTFOLIO 195
15.8.4 RECENT DEVELOPMENT 195
15.9 B. BRAUN SE 196
15.9.1 COMPANY SNAPSHOT 196
15.9.2 PRODUCT PORTFOLIO 196
15.9.3 RECENT UPDATES 197
15.10 DR. REDDY'S LABORATORIES LTD. 198
15.10.1 COMPANY SNAPSHOT 198
15.10.2 REVENUE ANALYSIS 198
15.10.3 PIPELINE PRODUCT PORTFOLIO 199
15.10.4 RECENT DEVELOPMENT 199
15.11 ICU MEDICAL, INC. 200
15.11.1 COMPANY SNAPSHOT 200
15.11.2 REVENUE ANALYSIS 200
15.11.3 PRODUCT PORTFOLIO 201
15.11.4 RECENT DEVELOPMENT/NEWS 201
15.12 HIKMA PHARMACEUTICALS PLC 202
15.12.1 COMPANY SNAPSHOT 202
15.12.2 REVENUE ANALYSIS 202
15.12.3 PIPELINE PRODUCT PORTFOLIO 203
15.12.4 RECENT DEVELOPMENT 204
15.13 JEDUX PARENTERAL PRIVATE LIMITED 205
15.13.1 COMPANY SNAPSHOT 205
15.13.2 PRODUCT PORTFOLIO 205
15.13.3 RECENT DEVELOPMENT 205
15.14 LUPIN 206
15.14.1 COMPANY SNAPSHOT 206
15.14.2 REVENUE ANALYSIS 206
15.14.3 PRODUCT PORTFOLIO 207
15.14.4 RECENT DEVELOPMENT 210
15.15 MERZ THERAPEUTICS 211
15.15.1 COMPANY SNAPSHOT 211
15.15.2 PIPELINE PRODUCT PORTFOLIO 211
15.15.3 RECENT DEVELOPMENT 211
15.16 MAXZIMAA 212
15.16.1 COMPANY SNAPSHOT 212
15.16.2 PIPELINE PRODUCT PORTFOLIO 212
15.16.3 RECENT DEVELOPMENT 213
15.17 SUN PHARMACEUTICAL INDUSTRIES LTD. 214
15.17.1 COMPANY SNAPSHOT 214
15.17.2 REVENUE ANALYSIS 214
15.17.3 PRODUCT PORTFOLIO 215
15.17.4 RECENT DEVELOPMENT 216
15.18 SWISS PHARMA NIGERIA LIMITED 217
15.18.1 COMPANY SNAPSHOT 217
15.18.2 PRODUCT PORTFOLIO 217
15.18.3 RECENT DEVELOPMENT 217
15.19 SAGENT 218
15.19.1 COMPANY SNAPSHOT 218
15.19.2 PRODUCT PORTFOLIO 218
15.19.3 RECENT DEVELOPMENT 221
16 QUESTIONNAIRE 222
17 RELATED REPORTS 225
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.